Uwe Meya named SynaptixBio CMO

SynaptixBio, a UK biotech that claims to be the world’s only company developing a therapy for TUBB4A-related leukodystrophies, has appointed Uwe Meya (pictured above) as chief medical officer (CMO).

In a career spanning almost 40 years, Dr Meya has worked for major international biotech firms in clinical research and development for neurological and psychiatric indications.

He is a qualified neurologist and psychiatrist with five and a half years of clinical tenure in academia and has written or co-written more than 30 peer-reviewed scientific and medical papers, which have been published in Lancet Neurology, Journal of Clinical Psychiatry, Movement Disorders and elsewhere.